IONIS PHARMACEUTICALS INC (IONS)
$61.05-$1.38 (-2.21%) Today
Michael R. Hayden - DirectorMichael R. Hayden - Director
Holly B. Kordasiewicz - OfficerIonis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 2 | 20,000 | $1.06M |
| Open-market sale | 17 | 250,316 | $19.68M |
| Grant or award | 18 | 81,994 | |
| Option exercise | 32 | 452,374 | |
| Other acquisition / disposition | 2 | 30,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
154 Form 4 filings on record, the earliest from Oct 1, 2024, newest first. Filing history page 1 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Michael R. Hayden - Director | Open-market purchase | Common Stock | 15,000 | $53.38 | $801K | |
| Michael R. Hayden - Director | Open-market purchase | Common Stock | 5,000 | $51.60 | $258K | |
| Peter N. Reikes - Director | Grant or award | Restricted Stock Unit | 3,399 | $0.00 | - | |
 Ludwig Hantson - Director | Grant or award | Restricted Stock Unit | 3,399 | $0.00 | - | |
| Joan E. Herman - Director | Option exercise | Common Stock | 5,220 | $0.00 | - | |
| Joan E. Herman - Director | Option exercise | Restricted Stock Unit | 5,220 | $0.00 | - | |
 Spencer R. Berthelsen - Director | Option exercise | Common Stock | 5,220 | $0.00 | - | |
| Spencer R. Berthelsen - Director | Option exercise | Restricted Stock Unit | 5,220 | $0.00 | - | |
| C. Frank Bennett - Officer | Open-market sale | Common Stock | 5,536 | $83.58 | $463K | |
| C. Frank Bennett - Officer | Other | Common Stock | 15,000 | $0.00 | - | |
| C. Frank Bennett - Officer | Open-market sale | Common Stock | 15,000 | $85.46 | $1.28M | |
| C. Frank Bennett - Officer | Other | Restricted Stock Unit | 15,000 | $0.00 | - | |
| Allene M. Diaz - Director | Option exercise | Common Stock | 10,111 | $47.11 | $476K | |
| Allene M. Diaz - Director | Option exercise | Non-Qualified Stock Option (right to buy) | 10,111 | $0.00 | - | |
| Allene M. Diaz - Director | Open-market sale | Common Stock | 10,111 | $85.42 | $864K | |
| Holly B. Kordasiewicz - Officer | Open-market sale | Common Stock | 362 | $84.30 | $31K | |
| Michael J. Yang - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 5,369 | $0.00 | - | |
| Michael J. Yang - Director | Grant or award | Restricted Stock Unit | 2,301 | $0.00 | - | |
| Joseph Loscalzo - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 5,369 | $0.00 | - | |
| Joseph Loscalzo - Director | Grant or award | Restricted Stock Unit | 2,301 | $0.00 | - | |
| Joan E. Herman - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 5,369 | $0.00 | - | |
| Joan E. Herman - Director | Grant or award | Restricted Stock Unit | 2,301 | $0.00 | - | |
| Joseph Klein III - Director | Option exercise | Common Stock | 11,518 | $39.94 | $460K | |
| Joseph Klein III - Director | Option exercise | Non-Qualified Stock Option (right to buy) | 11,518 | $0.00 | - | |
| Joseph Klein III - Director | Open-market sale | Common Stock | 99 | $79.45 | $8K | |
| Joseph Klein III - Director | Open-market sale | Common Stock | 11,419 | $79.04 | $903K | |
| Joseph Klein III - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 5,369 | $0.00 | - | |
| Joseph Klein III - Director | Grant or award | Restricted Stock Unit | 2,301 | $0.00 | - | |
| Michael R. Hayden - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 5,369 | $0.00 | - | |
| Michael R. Hayden - Director | Grant or award | Restricted Stock Unit | 2,301 | $0.00 | - | |
| Allene M. Diaz - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 5,369 | $0.00 | - | |
| Allene M. Diaz - Director | Grant or award | Restricted Stock Unit | 2,301 | $0.00 | - | |
| Spencer R. Berthelsen - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 5,369 | $0.00 | - | |
| Spencer R. Berthelsen - Director | Grant or award | Restricted Stock Unit | 2,301 | $0.00 | - | |
| Joseph Baroldi - Officer | Option exercise | Common Stock | 3,866 | $56.78 | $220K | |
| Joseph Baroldi - Officer | Option exercise | Common Stock | 1,769 | $32.60 | $58K | |
| Joseph Baroldi - Officer | Open-market sale | Common Stock | 5,635 | $80.16 | $452K | |
| Joseph Baroldi - Officer | Option exercise | Non-Qualified Stock Option (right to buy) | 1,769 | $0.00 | - | |
| Joseph Baroldi - Officer | Option exercise | Non-Qualified Stock Option (right to buy) | 3,866 | $0.00 | - | |
| Patrick R. O'Neil - Officer | Open-market sale | Common Stock | 3,069 | $80.00 | $246K | |
| Eugene Schneider - Officer | Option exercise | Common Stock | 26,000 | $60.89 | $1.58M | |
| Eugene Schneider - Officer | Option exercise | Non-Qualified Stock Option (right to buy) | 26,000 | $0.00 | - | |
| Eugene Schneider - Officer | Open-market sale | Common Stock | 26,000 | $81.05 | $2.11M | |
 Brett P. Monia - Officer | Option exercise | Common Stock | 14,565 | $32.60 | $475K | |
| Brett P. Monia - Officer | Option exercise | Common Stock | 21,072 | $32.60 | $687K | |
| Brett P. Monia - Officer | Option exercise | Common Stock | 50,000 | $56.78 | $2.84M | |
| Brett P. Monia - Officer | Option exercise | Non-Qualified Stock Option (right to buy) | 14,565 | $0.00 | - | |
| Brett P. Monia - Officer | Option exercise | Non-Qualified Stock Option (right to buy) | 21,072 | $0.00 | - | |
| Brett P. Monia - Officer | Option exercise | Non-Qualified Stock Option (right to buy) | 50,000 | $0.00 | - | |
| Brett P. Monia - Officer | Open-market sale | Common Stock | 14,565 | $78.41 | $1.14M | |
| Brett P. Monia - Officer | Open-market sale | Common Stock | 21,072 | $78.49 | $1.65M | |
| Brett P. Monia - Officer | Open-market sale | Common Stock | 50,000 | $80.59 | $4.03M | |
 Eric Swayze - Officer | Open-market sale | Common Stock | 10,602 | $79.18 | $839K | |
| Holly B. Kordasiewicz - Officer | Option exercise | Common Stock | 7,951 | $60.89 | $484K | |
| Holly B. Kordasiewicz - Officer | Option exercise | Common Stock | 21,000 | $60.89 | $1.28M | |
| Holly B. Kordasiewicz - Officer | Option exercise | Common Stock | 12,000 | $32.60 | $391K | |
| Holly B. Kordasiewicz - Officer | Option exercise | Common Stock | 19,895 | $56.78 | $1.13M | |
| Holly B. Kordasiewicz - Officer | Option exercise | Non-Qualified Stock Option (right to buy) | 12,000 | $0.00 | - | |
| Holly B. Kordasiewicz - Officer | Option exercise | Non-Qualified Stock Option (right to buy) | 19,895 | $0.00 | - | |
| Holly B. Kordasiewicz - Officer | Option exercise | Non-Qualified Stock Option (right to buy) | 7,951 | $0.00 | - | |
| Holly B. Kordasiewicz - Officer | Option exercise | Non-Qualified Stock Option (right to buy) | 21,000 | $0.00 | - | |
| Holly B. Kordasiewicz - Officer | Open-market sale | Common Stock | 41,004 | $73.09 | $3.00M | |
| Holly B. Kordasiewicz - Officer | Open-market sale | Common Stock | 19,842 | $74.05 | $1.47M | |
| Spencer R. Berthelsen - Director | Option exercise | Common Stock | 8,000 | $24.42 | $195K | |
| Spencer R. Berthelsen - Director | Option exercise | Non-Qualified Stock Option (right to buy) | 8,000 | $0.00 | - | |
| Spencer R. Berthelsen - Director | Open-market sale | Common Stock | 8,000 | $73.49 | $588K | |
| Peter N. Reikes - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 10,753 | $0.00 | - | |
| Ludwig Hantson - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 10,753 | $0.00 | - | |
| Spencer R. Berthelsen - Director | Option exercise | Common Stock | 8,000 | $24.42 | $195K | |
| Spencer R. Berthelsen - Director | Option exercise | Non-Qualified Stock Option (right to buy) | 8,000 | $0.00 | - | |
| Spencer R. Berthelsen - Director | Open-market sale | Common Stock | 8,000 | $75.67 | $605K | |
| Brett P. Monia - Officer | Option exercise | Common Stock | 1,316 | $32.60 | $43K | |
| Brett P. Monia - Officer | Option exercise | Common Stock | 3,220 | $32.60 | $105K | |
| Brett P. Monia - Officer | Option exercise | Non-Qualified Stock Option (right to buy) | 1,316 | $0.00 | - | |
| Brett P. Monia - Officer | Option exercise | Non-Qualified Stock Option (right to buy) | 3,220 | $0.00 | - | |
| Brett P. Monia - Officer | Open-market sale | Common Stock | 1,316 | $78.01 | $103K | |
| Brett P. Monia - Officer | Open-market sale | Common Stock | 3,220 | $78.68 | $253K | |
| Joseph Loscalzo - Director | Option exercise | Common Stock | 10,968 | $38.06 | $417K | |
| Joseph Loscalzo - Director | Option exercise | Common Stock | 12,000 | $40.05 | $481K | |
| Joseph Loscalzo - Director | Option exercise | Common Stock | 10,321 | $41.08 | $424K | |
| Joseph Loscalzo - Director | Option exercise | Common Stock | 16,000 | $42.88 | $686K | |
| Joseph Loscalzo - Director | Option exercise | Common Stock | 12,000 | $60.20 | $722K | |
| Joseph Loscalzo - Director | Option exercise | Common Stock | 16,000 | $64.80 | $1.04M | |
| Joseph Loscalzo - Director | Option exercise | Non-Qualified Stock Option (right to buy) | 10,968 | $0.00 | - | |
| Joseph Loscalzo - Director | Option exercise | Non-Qualified Stock Option (right to buy) | 12,000 | $0.00 | - | |
| Joseph Loscalzo - Director | Option exercise | Non-Qualified Stock Option (right to buy) | 10,321 | $0.00 | - | |
| Joseph Loscalzo - Director | Option exercise | Non-Qualified Stock Option (right to buy) | 16,000 | $0.00 | - | |
| Joseph Loscalzo - Director | Option exercise | Non-Qualified Stock Option (right to buy) | 12,000 | $0.00 | - | |
| Joseph Loscalzo - Director | Option exercise | Non-Qualified Stock Option (right to buy) | 16,000 | $0.00 | - | |
| Joseph Loscalzo - Director | Open-market sale | Common Stock | 59,508 | $74.90 | $4.46M | |
| Joseph Loscalzo - Director | Open-market sale | Common Stock | 17,781 | $75.58 | $1.34M | |
| Joseph Klein III - Director | Option exercise | Common Stock | 10,111 | $47.11 | $476K | |
| Joseph Klein III - Director | Option exercise | Non-Qualified Stock Option (right to buy) | 10,111 | $0.00 | - | |
| Joseph Klein III - Director | Open-market sale | Common Stock | 8,680 | $73.35 | $637K | |
| Joseph Klein III - Director | Open-market sale | Common Stock | 1,431 | $74.45 | $107K | |
 B. Lynne Parshall - Director | Open-market sale | Common Stock | 4,466 | $76.19 | $340K | |
| B. Lynne Parshall - Director | Open-market sale | Common Stock | 534 | $76.97 | $41K | |
| Kyle Jenne - Officer | Option exercise | Common Stock | 12,226 | $0.00 | - | |
| Kyle Jenne - Officer | Open-market sale | Common Stock | 4,902 | $75.17 | $368K | |
| Kyle Jenne - Officer | Option exercise | Restricted Stock Unit | 12,226 | $0.00 | - |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
IONIS PHARMACEUTICALS INC (IONS) had 25 insider filings in the last 90 days, with the most recent on 2026-07-31. The full record for IONS runs to 154 Form 4 filings, the earliest from 2024-10-01. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
2 insider purchases of IONS were filed in the last 90 days, totaling $1.06M.
17 insider sales of IONS were filed in the last 90 days, totaling $19.68M.
This page tracks IONS Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add IONS to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
